Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Disease definitions in respiratory and sleep medicine: changes in diagnostic criteria and categories over time and clinical implications

Claudia C. Dobler
Breathe 2021 17: 210117; DOI: 10.1183/20734735.0117-2021
Claudia C. Dobler
1The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
2Dept of Respiratory and Sleep Medicine, Liverpool Hospital, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Claudia C. Dobler
  • For correspondence: c.dobler@unsw.edu.au
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The latest issue of Breathe focuses on disease definitions in respiratory and sleep medicine: read the introductory editorial by Chief Editor @ClaudiaCDobler https://bit.ly/3A7CeYj

We often think of disease definitions as absolute and unchangeable, however, diagnostic criteria and categories for diseases are not static [1]. They change over time, and different definitions can coexist at the same time.

Have you ever wondered how diseases get defined? Often definitions are based on several diagnostic criteria, which might include symptoms and/or results of diagnostic tests. They are created and revised by expert panels, for example guideline committees or professional society groups. Determining the presence of disease is not always as straightforward as one might think. How “high” does the pulmonary arterial pressure have to be before it is pulmonary hypertension? How many apnoeas and hypopnoeas are considered “normal” during sleep and when is it labelled obstructive sleep apnoea?

Changes in disease definitions/diagnostic criteria can significantly impact the conceptualisation of a condition. For example, the inclusion of symptoms as a diagnostic requirement means that asymptomatic patients do not receive a disease label. The change of thresholds to distinguish normal variation from disease can change the incidence and prevalence of a disease, as well as the perceived effectiveness of treatment. For example, as the forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio is known to decline with age, the prevalence of COPD in a population could be higher when using the fixed FEV1/FVC ratio compared with using an age-adjusted definition of airflow obstruction or the lower limit of normal [2]. Including earlier and/or milder disease cases by lowering disease thresholds might bias results to suggest better treatment efficacy.

Widening disease definitions to include early disease stages (e.g. pre-diabetes, pre-hypertension, pre-COPD) has the potential to allow earlier detection and treatment of a disease, but potential harms from overdiagnosis also need to be considered [3]. An evidence-based systematic evaluation of the benefits and harms before widening disease definitions is therefore indicated.

Disease labels help to define groups of patients who will benefit from specific treatments. Inconsistencies in definitions of diseases/clinical conditions in clinical trials may therefore have consequences for the applicability of the results. The article “Towards precision in defining COPD exacerbations” in this issue of Breathe outlines the challenges of finding a standardised definition for what constitutes an exacerbation of COPD [4], an important disease state and outcome measure in clinical trials because of its impact on patients and health systems.

Other articles in this issue explore the definitions of pulmonary hypertension, obstructive sleep apnoea, and latent tuberculosis infection [5–7], outlining how these disease labels and categories evolved over time, and how changes in diagnostic criteria impact on clinical practice. The article “Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease” puts forward the idea that umbrella terms such as “asthma” or “COPD” should be replaced by the concept of treatable traits [8]. The lung function corner article in this issue on the “Pathophysiology of pulmonary function anomalies in COVID-19 survivors” proposes COVID-19 phenotypes based on different types of lung function abnormalities found in survivors [9].

With this issue, my tenure as Chief editor of Breathe, the leading educational journal for respiratory professionals, is coming to an end. It has been a privilege to serve in this role for the past 3 years. I wish the incoming Chief editor Brian Kent all the best for this challenging but fulfilling role. Based on my experience of working with Brian on the Editorial board of Breathe, I have no doubt that he will do an outstanding job taking the journal into the future. I would like to express my sincere gratitude to the hard-working publications team at the Sheffield office for their invaluable support over the past 3 years, especially during the difficult time of the COVID-19 pandemic. I would also like to thank all Editorial board members; in particular, Andrea Aliverti and Pierantonio Laveneziana, the Section editors for the Lung function corner, Jayesh Bhatt, who has been doing a fantastic job commissioning and managing paediatric contributions, and Frits Franssen and Alexander Mathioudakis, the former and current Section editor for the journal club papers. Thanks to all the reviewers, contributors, and readers of Breathe. It is my hope that you, our reader, find the journal content useful in your everyday clinical practice.

Footnotes

  • Conflict of interest: C.C. Dobler has nothing to disclose.

  • Received August 2, 2021.
  • Accepted August 2, 2021.
  • Copyright ©ERS 2021
http://creativecommons.org/licenses/by-nc/4.0/

Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Tresker S
    . A typology of clinical conditions. Stud Hist Philos Biol Biomed Sci 2020; 83: 101291. doi:10.1016/j.shpsc.2020.101291
    OpenUrl
  2. ↵
    1. Thomas ET,
    2. Glasziou P,
    3. Dobler CC
    . Use of the terms “overdiagnosis” and “misdiagnosis” in the COPD literature: a rapid review. Breathe 2019; 15: e8–e19. doi:10.1183/20734735.0354-2018
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Dobler CC,
    2. Glasziou PP
    . Overdiagnosis in respiratory medicine. Respirology 2019; 24: 939–941. doi:10.1111/resp.13623
    OpenUrl
  4. ↵
    1. Jenkins CR
    . Towards precision in defining COPD exacerbations. Breathe 2021; 17: 210081. doi:10.1183/20734735.0081-2021
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. , Olschewski H
    1. Kovacs G
    , Olschewski H. The definition of pulmonary hypertension: history, practical implications and current controversies. Breathe 2021; 17: 210076. doi:10.1183/20734735.0076-2021
    OpenUrlAbstract/FREE Full Text
    1. Riha RL
    . Defining obstructive sleep apnoea syndrome: a failure of semantic rules. Breathe 2021; 17: 210082. doi:10.1183/20734735.0082-2021
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Migliori GB,
    2. Ong CWM,
    3. Petrone L, et al.
    The definition of tuberculosis infection based on the spectrum of tuberculosis disease. Breathe 2021; 17: 210079. doi:10.1183/20734735.0079-2021
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Bush A,
    2. Pavord ID
    . Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease. Breathe 2021; 17: 210053. doi:10.1183/20734735.0053-2021
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Laveneziana P,
    2. Sesé L,
    3. Gille T
    . Pathophysiology of pulmonary function anomalies in COVID-19 survivors. Breathe 2021; 17: 210065. doi:10.1183/20734735.0065-2021
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Vol 17 Issue 3 Table of Contents
Breathe: 17 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Disease definitions in respiratory and sleep medicine: changes in diagnostic criteria and categories over time and clinical implications
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Disease definitions in respiratory and sleep medicine: changes in diagnostic criteria and categories over time and clinical implications
Claudia C. Dobler
Breathe Sep 2021, 17 (3) 210117; DOI: 10.1183/20734735.0117-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Disease definitions in respiratory and sleep medicine: changes in diagnostic criteria and categories over time and clinical implications
Claudia C. Dobler
Breathe Sep 2021, 17 (3) 210117; DOI: 10.1183/20734735.0117-2021
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Pulmonary vascular disease for the general respiratory clinician
  • Sleep medicine in Europe: 50 years of evolution
  • Managing respiratory disease in pregnancy
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2023 by the European Respiratory Society